TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12635120

Group type: EXPERIMENTAL
Intervention: Progressive resistance training (three sets of eight isometric contractions, three times weekly for 12 weeks)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 10
Study: 11124694

Group type: EXPERIMENTAL
Intervention: Preoperative apheresis with hemodilution using 4% albumin, retrieving c‐PRP and 2 units of ERC.
Number of subjects: 80

Group type: COMPARATOR
Intervention: Preoperative autologous donation (PAD) with 2 units of ERC + plasma retrieved within 4 weeks preoperatively.
Number of subjects: 80
Study: 9338422

Group type: EXPERIMENTAL
Intervention: 25-ml Bioenervi treatment (125 ml contained 25 ml Bioenervi)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 125-ml Bioenervi treatment (125 ml contained 125 ml Bioenervi)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo (normal milk whey) treatment
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: All treatments (25-ml Bioenervi, 125-ml Bioenervi, and placebo)
Number of subjects: 9
Study: 8452062

Group type: EXPERIMENTAL
Intervention: guaifenesin
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: guaifenesin plus codeine
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: guaifenesin plus dextromethorphan
Number of subjects: 97
Study: 3455114

Group type: EXPERIMENTAL
Intervention: AAFP's 'Competitive Edge' marketing package (two marketing brochures)
Number of subjects: 466

Group type: COMPARATOR
Intervention: Control group (no marketing brochures)
Number of subjects: 466
Study: 29421993

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (30 mg Zn gluconate per day)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (maltose dextrin per day)
Number of subjects: 50
Study: 29030386

Group type: EXPERIMENTAL
Intervention: Wahakura
Number of subjects: 200

Group type: COMPARATOR
Intervention: Bassinet
Number of subjects: 200
Study: 27338747

Group type: EXPERIMENTAL
Intervention: BCAA (Branched-Chain Amino Acids)
Number of subjects: 77

Group type: COMPARATOR
Intervention: non-BCAA
Number of subjects: 77
Study: 24102423

Group type: EXPERIMENTAL
Intervention: 12-week exercise program including aerobic and strengthening exercises, conducted between the 20th and 36th week of gestation.
Number of subjects: 855

Group type: COMPARATOR
Intervention: Standard antenatal care (Control)
Number of subjects: 855
Study: 22143109

Group type: EXPERIMENTAL
Intervention: Pedometry and buddy support
Number of subjects: 399

Group type: EXPERIMENTAL
Intervention: Pedometry and no buddy
Number of subjects: 399

Group type: EXPERIMENTAL
Intervention: Buddy peer support intervention
Number of subjects: 399

Group type: COMPARATOR
Intervention: Control groups (no pedometry and no buddy)
Number of subjects: 399
Study: 20159045

Group type: EXPERIMENTAL
Intervention: 3D electroanatomical mapping (Carto)
Number of subjects: 91

Group type: COMPARATOR
Intervention: 3DATG
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Carto
Number of subjects: 91
Study: 17284557

Group type: EXPERIMENTAL
Intervention: Inductive reasoning training
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Spatial orientation training
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Combination of reasoning ability training and increased proximal training gain
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Reasoning ability training
Number of subjects: 302
Study: 16122642

Group type: EXPERIMENTAL
Intervention: Moderated e-mail discussion group
Number of subjects: 421

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 421
Study: 11485054

Group type: EXPERIMENTAL
Intervention: 900 mg Hypericum perforatum L. (St. John's Wort)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 1800 mg Hypericum perforatum L. (St. John's Wort)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 9806319

Group type: EXPERIMENTAL
Intervention: All foods eaten with varying fat content (20%, 40%, 60%)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Lunch meal with varying fat content (20%, 40%, 60%)
Number of subjects: 5
Study: 7841567

Group type: EXPERIMENTAL
Intervention: Predictive dosing
Number of subjects: 18

Group type: COMPARATOR
Intervention: Empiric dosing
Number of subjects: 18
Study: 3063541

Group type: EXPERIMENTAL
Intervention: Estrogens
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Radiotherapy
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Orchiectomy
Number of subjects: 151

Group type: COMPARATOR
Intervention: Orchiectomy, Estrogens, Radiotherapy
Number of subjects: 151
Study: 29597104

Group type: EXPERIMENTAL
Intervention: ImpACT (Improving AIDS Care after Trauma) intervention; details on dosage and duration not specified
Number of subjects: 0
Study: 27244298

Group type: EXPERIMENTAL
Intervention: Iron supplementation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pediatric Sleep CGI
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Actigraphy sleep onset delay scores
Number of subjects: 0
Study: 24117522

Group type: EXPERIMENTAL
Intervention: Key-press action (self-action)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 85 dB noise burst (auditory prestimulus)
Number of subjects: 0
Study: 22467778

Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 5000

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5000
Study: 20573338

Group type: EXPERIMENTAL
Intervention: One‐Session Treatment (OST)
Number of subjects: 100
Study: 17696986

Group type: EXPERIMENTAL
Intervention: Peer assessment
Number of subjects: 336

Group type: COMPARATOR
Intervention: No peer assessment
Number of subjects: 336
Study: 16088037

Group type: EXPERIMENTAL
Intervention: 5 mg vardenafil
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 10 mg vardenafil
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 20 mg vardenafil
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 12535027

Group type: EXPERIMENTAL
Intervention: L-cysteine-HCl 500 mg in two divided doses per day
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 10792120

Group type: EXPERIMENTAL
Intervention: Midazolam 0.03 mg/kg bolus followed by 0.015 mg/kg after 1.5, 3 and 4.5 h
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 8665630

Group type: EXPERIMENTAL
Intervention: Meperidine 0.8 mg.kg‐1
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Meperidine 0.4 mg.kg‐1 plus 1.5 ml of 0.5% heavy bupivacaine
Number of subjects: 42

Group type: COMPARATOR
Intervention: 3 ml of heavy bupivacaine 0.5%
Number of subjects: 42
Study: 1316574

Group type: EXPERIMENTAL
Intervention: Human leucocyte alpha-interferon treatment; specific dosage and duration not mentioned.
Number of subjects: 0
Study: 6415738

Group type: EXPERIMENTAL
Intervention: Piracetam 2.4 g/day
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Piracetam 4.8 g/day
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 30351408

Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccination (≥1 dose)
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Complete vaccination (all three doses)
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Chronic HBV infection
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Protective anti-HBs levels
Number of subjects: 312

Group type: COMPARATOR
Intervention: Working in hospitals vs primary healthcare facilities
Number of subjects: 312
Study: 29165853

Group type: EXPERIMENTAL
Intervention: PDMP opioid prescriptions (at least one prescription in the past year)
Number of subjects: 329

Group type: EXPERIMENTAL
Intervention: PDMP opioid prescriptions (≥4 prescriptions)
Number of subjects: 329
Study: 27695865

Group type: EXPERIMENTAL
Intervention: Minoxidil 5% topical foam, applied daily (1 ml) for 6 months
Number of subjects: 17
Study: 25034716

Group type: EXPERIMENTAL
Intervention: Diabetes mellitus
Number of subjects: 3020

Group type: COMPARATOR
Intervention: Patients without diabetes mellitus
Number of subjects: 3020
Study: 22658432

Group type: EXPERIMENTAL
Intervention: Topiramate 100 mg oral dose
Number of subjects: 0
Study: 19640271

Group type: EXPERIMENTAL
Intervention: Cardiovascular magnetic resonance (CMR)
Number of subjects: 750

Group type: COMPARATOR
Intervention: Single photon emission tomography (SPECT)
Number of subjects: 750

Group type: COMPARATOR
Intervention: Exercise tolerance testing (ETT)
Number of subjects: 750
Study: 17458795

Group type: EXPERIMENTAL
Intervention: 25-gauge ppv (group 1 and group 2)
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: 25-gauge ppv (group 3)
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: 25-gauge ppv
Number of subjects: 139

Group type: COMPARATOR
Intervention: 20-gauge ppv
Number of subjects: 139
Study: 16050857

Group type: EXPERIMENTAL
Intervention: PRIME‐MD Anxiety Module
Number of subjects: 1216

Group type: EXPERIMENTAL
Intervention: SIGH‐A
Number of subjects: 1216

Group type: EXPERIMENTAL
Intervention: PDSS
Number of subjects: 1216

Group type: EXPERIMENTAL
Intervention: PCP agreement with PRIME‐MD diagnosis
Number of subjects: 1216
Study: 11641099

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 9313600

Group type: EXPERIMENTAL
Intervention: Recombinant staphylokinase (two 15 mg doses, 30 minutes apart)
Number of subjects: 102

Group type: COMPARATOR
Intervention: rTPA (intravenous front‐loaded, weight‐adjusted administration over 90 minutes)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Recombinant staphylokinase
Number of subjects: 102

Group type: COMPARATOR
Intervention: rTPA
Number of subjects: 102
Study: 8420615

Group type: EXPERIMENTAL
Intervention: Calcium supplementation (1200 mg of calcium daily)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 3945530

Group type: EXPERIMENTAL
Intervention: Albuterol
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Metaproterenol sulfate
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 2742167

Group type: EXPERIMENTAL
Intervention: 7.5‐10 mg of 0.5% hyperbaric bupivacaine (Group A)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 10‐12.5 mg of 0.5% hyperbaric bupivacaine (Group B)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 36
Study: 31826853

Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept or ranibizumab (anti-VEGF agents)
Number of subjects: 2373
Study: 31665143

Group type: EXPERIMENTAL
Intervention: JUMP Math
Number of subjects: 1146

Group type: COMPARATOR
Intervention: Business-as-usual, problem-based approach
Number of subjects: 1146
Study: 29798407

Group type: EXPERIMENTAL
Intervention: Guided self rehabilitation training (Group B)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Brandt Daroff training (Group C)
Number of subjects: 98

Group type: COMPARATOR
Intervention: No disposition (Control group A)
Number of subjects: 98
Study: 25173761

Group type: EXPERIMENTAL
Intervention: Disodium folinate 20 mg/m(2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Disodium folinate 200 mg/m(2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Disodium folinate 300 mg/m(2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adverse events (AEs)
Number of subjects: 0
Study: 23435218

Group type: EXPERIMENTAL
Intervention: Mouth-to-mouth ventilation (MMV)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Bag-mask ventilation (BMV)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Laryngeal tube ventilation (LTV)
Number of subjects: 19

Group type: COMPARATOR
Intervention: No ventilation (NV)
Number of subjects: 19
Study: 21651729

Group type: EXPERIMENTAL
Intervention: Pre-operative tissue expansion using DynaClose Expansion System
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (unexpanded radial forearm free-flap donor sites)
Number of subjects: 34
Study: 17934184

Group type: EXPERIMENTAL
Intervention: Atomoxetine (0.5-1.5 mg/kg/day)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117
Study: 17065669

Group type: EXPERIMENTAL
Intervention: ALA600 (600 mg once daily)
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: ALA1200 (1200 mg once daily)
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: ALA1800 (1800 mg once daily)
Number of subjects: 181

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 181
Study: 14676592

Group type: EXPERIMENTAL
Intervention: Zinc treatment (15 mg for ≤12 months, 30 mg for >12 months)
Number of subjects: 287
Study: 10936785

Group type: EXPERIMENTAL
Intervention: Systematic random map-biopsy
Number of subjects: 102

Group type: COMPARATOR
Intervention: RDE positive cases
Number of subjects: 102

Group type: COMPARATOR
Intervention: RDE negative cases
Number of subjects: 102
Study: 10072830

Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg Bid)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Placebo (one tablet Bid)
Number of subjects: 202
Study: 8335201

Group type: EXPERIMENTAL
Intervention: Ketanserin
Number of subjects: 12
Study: 3511284

Group type: EXPERIMENTAL
Intervention: Intravesical bacillus Calmette-Guerin (120 mg in 50 ml saline) weekly for 6 weeks
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Combined bacillus Calmette-Guerin
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Intravesical bacillus Calmette-Guerin alone
Number of subjects: 47

Group type: COMPARATOR
Intervention: Transurethral resection and fulguration alone (control group)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Randomized study group (intravesical and percutaneous bacillus Calmette-Guerin)
Number of subjects: 47
Study: 31010436

Group type: EXPERIMENTAL
Intervention: miRNA‐933
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: miRNA‐191‐3p, miRNA‐933, and miRNA‐425‐3p
Number of subjects: 290
Study: 28610968

Group type: EXPERIMENTAL
Intervention: Sensory-level NMES
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Motor-level NMES
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 66
Study: 26742981

Group type: EXPERIMENTAL
Intervention: Laparoscopic nephrectomy (LN)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Open nephrectomy (ON)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups (LN and ON)
Number of subjects: 40
Study: 23167718

Group type: EXPERIMENTAL
Intervention: High-dose intravenous oxytocin
Number of subjects: 180

Group type: COMPARATOR
Intervention: Dinoprostone-only vaginal pessary
Number of subjects: 180
Study: 21329837

Group type: EXPERIMENTAL
Intervention: Double Kissing Crush (DK)
Number of subjects: 370

Group type: COMPARATOR
Intervention: Provisional Stenting (PS)
Number of subjects: 370
Study: 18384910

Group type: EXPERIMENTAL
Intervention: Printed advertisements for less healthy foods
Number of subjects: 309

Group type: COMPARATOR
Intervention: Printed advertisements for healthy foods
Number of subjects: 309

Group type: COMPARATOR
Intervention: Printed advertisements for non-food products
Number of subjects: 309
Study: 16817266

Group type: EXPERIMENTAL
Intervention: Electro-round-needling
Number of subjects: 89

Group type: COMPARATOR
Intervention: Western medication
Number of subjects: 89
Study: 12556776

Group type: EXPERIMENTAL
Intervention: Omeprazole (80 mg intravenous bolus followed by infusion at 8 mg/hour for 72 hours)
Number of subjects: 232

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 232
Study: 11524327

Group type: EXPERIMENTAL
Intervention: Ketamine (0.15 mg/kg IV just after the induction of anesthesia)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Vehicle placebo
Number of subjects: 50
Study: 9315993

Group type: EXPERIMENTAL
Intervention: Sertindole (4 mg dose increments up to 24 mg, maintained for 5 days, every other day for group 1)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Sertindole (4 mg dose increments up to 24 mg, maintained for 5 days, daily for group 2)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (during the 4-day washout period)
Number of subjects: 16
Study: 8478168

Group type: EXPERIMENTAL
Intervention: Barium enema (BE) examination
Number of subjects: 40

Group type: COMPARATOR
Intervention: Abdominal sonography before and after barium enema
Number of subjects: 40
Study: 2881897

Group type: EXPERIMENTAL
Intervention: Broxaterol 200 micrograms
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Broxaterol 400 micrograms
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 28935128

Group type: EXPERIMENTAL
Intervention: Aquatic aerobic training (n=17)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Dry-land aerobic training (n=18)
Number of subjects: 35
Study: 28468794

Group type: COMPARATOR
Intervention: Continue MTX (group 1)
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Suspend MTX for 4 weeks before vaccination (group 2)
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Suspend MTX for 2 weeks before and 2 weeks after vaccination (group 3)
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Suspend MTX for 4 weeks after vaccination (group 4)
Number of subjects: 199
Study: 26142239

Group type: EXPERIMENTAL
Intervention: Oxytocin administration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 23208074

Group type: EXPERIMENTAL
Intervention: Calcium (1000 mg elemental calcium carbonate) plus Vitamin D (400 IU of vitamin D(3))
Number of subjects: 36282

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36282
Study: 21331975

Group type: EXPERIMENTAL
Intervention: Additional manualized nine-session group intervention for complicated grief disorder
Number of subjects: 72

Group type: COMPARATOR
Intervention: Treatment as usual (control)
Number of subjects: 72
Study: 18177428

Group type: EXPERIMENTAL
Intervention: Axial implants
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Tilted implants
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Full-arch fixed bridge
Number of subjects: 41
Study: 16498589

Group type: EXPERIMENTAL
Intervention: Psychoeducational eating disturbance intervention
Number of subjects: 95

Group type: COMPARATOR
Intervention: Matched control sample
Number of subjects: 95
Study: 12728080

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (10 mg/L)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo (5 mg/L zinc)
Number of subjects: 36
Study: 11203652

Group type: EXPERIMENTAL
Intervention: Implant-supported prostheses with tooth connection
Number of subjects: 18

Group type: COMPARATOR
Intervention: Freestanding prostheses supported by implants
Number of subjects: 18
Study: 8695090

Group type: EXPERIMENTAL
Intervention: 15 mg trimethaphan
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 10 mg trimethaphan
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 5 mg trimethaphan
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 1798889

Group type: EXPERIMENTAL
Intervention: Training to sleep in the lateral position with the help of an alarm
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Encouraged to learn lateral sleep posture on their own
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Wearing a tongue retaining device (TRD)
Number of subjects: 60

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 60
Study: 31464703

Group type: EXPERIMENTAL
Intervention: 35% glycolic acid (GA) full-face peel
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 35% glycolic acid (GA) full-face peel followed by a 10% trichloroacetic acid (TCA) spot peel
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 35% glycolic acid (GA) full-face peel followed by a 20% trichloroacetic acid (TCA) spot peel
Number of subjects: 30
Study: 29282098

Group type: EXPERIMENTAL
Intervention: Maintaining serum potassium ≥ 3.6 mEq/L (relaxed control)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Maintaining serum potassium ≥ 4.5 mEq/L (tight control)
Number of subjects: 160
Study: 26333701

Group type: EXPERIMENTAL
Intervention: IgE-mediated food allergy confirmed through DBPCFC
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Food-induced asthma exacerbations
Number of subjects: 180

Group type: COMPARATOR
Intervention: Atopic dermatitis prevalence
Number of subjects: 180

Group type: COMPARATOR
Intervention: Urticaria prevalence
Number of subjects: 180

Group type: COMPARATOR
Intervention: Digestive symptoms prevalence
Number of subjects: 180

Group type: COMPARATOR
Intervention: Rhinitis prevalence
Number of subjects: 180

Group type: COMPARATOR
Intervention: sIgE level
Number of subjects: 180

Group type: COMPARATOR
Intervention: Positive family history of atopy
Number of subjects: 180

Group type: COMPARATOR
Intervention: FA in history
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Severity and control of asthma
Number of subjects: 180
Study: 23912284

Group type: EXPERIMENTAL
Intervention: Hypotonic maintenance fluids (0.45% NaCl/5% dextrose)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Isotonic maintenance fluids (0.9% NaCl/5% dextrose)
Number of subjects: 63
Study: 22031728

Group type: EXPERIMENTAL
Intervention: Annual posteroanterior view chest radiograph for 4 years
Number of subjects: 154901

Group type: COMPARATOR
Intervention: Usual care (no interventions)
Number of subjects: 154901

Group type: EXPERIMENTAL
Intervention: Subset of participants eligible for NLST
Number of subjects: 154901
Study: 19563707

Group type: EXPERIMENTAL
Intervention: Morphine 0.02 mg.kg(‐1).h(‐1) combined with ketamine 0.08 mg.kg(‐1).h(‐1) for 50 h (group mk)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Morphine 0.02 mg.kg(‐1).h(‐1) (group m)
Number of subjects: 30
Study: 17241184

Group type: EXPERIMENTAL
Intervention: Intracoronary enalaprilat (50 micro g)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 15266832

Group type: EXPERIMENTAL
Intervention: Arbidol (200 mg three times daily for 5 days)
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Arbidol
Number of subjects: 232

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 232
Study: 11890486

Group type: EXPERIMENTAL
Intervention: MDS-HC assessment
Number of subjects: 187

Group type: COMPARATOR
Intervention: Conventional geriatric assessment (Barthel, Lawton and Brody, MMSE)
Number of subjects: 187
Study: 9506732

Group type: EXPERIMENTAL
Intervention: Bromocriptine (2.5-10 mg/day)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Quinagolide (0.075-0.3 mg/day)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Cabergoline (0.5-1.5 mg/week)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 20
Study: 8792109

Group type: EXPERIMENTAL
Intervention: Thor‐Lo footwear
Number of subjects: 50